The therapeutic efficacy of resveratrol for acute lung injury—A meta−analysis of preclinical trials

Abstract

Background: Resveratrol (RES) has a protective effect on acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Our purpose was to conduct a meta−analysis to investigate the efficacy of RES for ALI/ARDS in animal models.Methods: PubMed, EMBASE and Web of Science were searched to screen relevant preclinical trials. The standardized mean difference (SMD) was used to compare the lung injury score, lung wet−dry weight ratio (W/D ratio), tumor necrosis factor−α (TNF−α), interleukin−1β (IL−1β), IL−6, IL−10, the number of neutrophils in bronchoalveolar lavage fluid (BALF) and the total protein in BALF between the treatment and control groups. SYRCLE’s risk of bias tool was used for quality assessment.Results: A total of 17 studies published from 2005 to 2021 were included in our study to calculate the SMD with corresponding confidence interval (CI). As compared with controls, RES significantly decreased the lung injury score (SMD −2.06; 95% CI −2.77, −1.35; p < 0.00001) and W/D ratio (SMD −1.92; 95% CI −2.62, −1.22; p < 0.00001). RES also reduced the number of neutrophils in BALF (SMD −3.03; 95% CI −3.83, −2.24; p < 0.00001) and the total protein in BALF (SMD −5.59; 95% CI −10.10, −1.08; p = 0.02). Furthermore, RES was found to downregulate proinflammatory mediators such as TNF−α (SMD −2.02; 95% CI −3.09, −0.95; p = 0.0002), IL−1β (SMD −2.51; 95% CI −4.00, −1.02; p = 0.001) and IL−6 (SMD −2.26; 95% CI −3.49, −1.04; p = 0.0003). But RES had little effect on the anti−inflammatory mediators such as IL−10 (SMD 2.80; 95% CI −0.04, 5.63; p = 0.05). Sensitivity analysis and stratified analysis were performed for the outcome indicators with heterogeneity.Conclusion: RES treatment is effective on reducing the severity of ALI. However, more animal studies and human trials are needed for further investigation. Our study may provide a reference for preclinical and clinical studies in the future to some extent.

Stand Up to Stand Out: Natural Dietary Polyphenols Curcumin, Resveratrol, and Gossypol as Potential Therapeutic Candidates against Severe Acute Respiratory Syndrome Coronavirus 2 Infection

“…Resveratrol (RSV), a polyphenolic nutraceutical mainly found in grapes ( Vitis vinifera L.) ( Figure 3 ), demonstrates health-promoting properties, including antioxidative [ 61 ], immunomodulatory [ 62 ], and anti-aging effects [ 63 ]. Since its association with the “French paradox” in 1992, resveratrol has received increasing research interest owing to its diverse pharmacological activities and multi-organ protective effects (e.g., acute lung injury [ 64 ], cerebral ischemia/reperfusion injury [ 65 ], myocardial cell apoptosis [ 66 ], and hepatic injury [ 67 ]). Resveratrol is classified as a food supplement with an excellent safety record and no serious adverse events even when administered in large doses (up to 600 mg per day) [ 68 ].…”

Destruction of the cellular antioxidant pool contributes to resveratrol‐induced senescence and apoptosis in lung cancer

“…A few studies have found that RES could prevent and treat various cancers, such as breast, gastric, colorectal, prostate, and lung cancers (Wu et al, 2022). Therefore, considering its low toxicity to normal tissues, RES has been used in preclinical and clinical research (Mansour et al, 2021; A. P. Singh et al, 2019; Tang et al, 2022).…”

“…Therefore, considering its low toxicity to normal tissues, RES has been used in preclinical and clinical research (Mansour et al, 2021;A. P. Singh et al, 2019;Tang et al, 2022).…”

Qinhuo Shanggan oral solution resolves acute lung injury by down-regulating TLR4/NF-κB signaling cascade and inhibiting NLRP3 inflammasome activation

“…Acute lung injury (ALI) is an acute inflammatory condition often triggered by severe infection or trauma. It is characterized by difficulty in breathing, respiratory distress, and damage to the alveolar epithelial barrier (1,2). The primary pathological features include acute widespread alveolar damage, pulmonary interstitial fluid accumulation, heightened pulmonary capillary permeability, and excessive inflammation (3,4).…”